Metallibure
Chemical compound
 | |
| Clinical data | |
|---|---|
| Trade names | Aimax, Suisynchron, Turisynchron |
| Other names | Methallibure; Methallibur; ICI-33828; AY-61122; NSC-69536 |
| Drug class | Antigonadotropin |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID |
|
| ChemSpider |
|
| UNII |
|
| ECHA InfoCard | 100.011.952  |
| Chemical and physical data | |
| Formula | C7H14N4S2 |
| Molar mass | 218.34 g·mol−1 |
| 3D model (JSmol) |
|
| |
InChI
| |
Metallibure (INNTooltip International Nonproprietary Name) (brand names Aimax, Suisynchron, Turisynchron; former developmental code names ICI-33828, AY-61122, NSC-69536), also known as methallibure (USANTooltip United States Adopted Name, BANTooltip British Approved Name) or methallibur (German), is a medication which was introduced in 1973 and has been used in veterinary medicine to synchronize estrus.[1][2] It was withdrawn in the United States and Europe due to teratogenicity and has been replaced with altrenogest (Regumate, Matrix), a progestin.[2][3]
The precise mechanism of action of metallibure is unknown.[2] It has been described as a "nonsteroidal antigonadotropin" and it appears to act directly on the pituitary gland and/or hypothalamus to suppress gonadotropin secretion.[2] However, metallibure has also been reported to be an antiprogestogen and to act specifically via inhibition of the biosynthesis or secretion of progesterone.[4]
Metallibure has similar endocrinological effects in women.[5] It is associated with several unpleasant side effects including appetite loss, nausea, occasional vomiting, lethargy, and drowsiness.[5] Animal toxicity studies revealed that the medication induced the development of cataracts, and this resulted in the termination of its clinical development.[5]
See also
References
- ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 781–. ISBN 978-1-4757-2085-3.
- ^ a b c d I. Gordon (22 October 2013). Controlled Breeding in Farm Animals. Elsevier. pp. 313–. ISBN 978-1-4832-8569-6.
- ^ Brüssow KP, Schneider F, Kanitz W, Rátky J, Kauffold J, Wähner M (2009). "Studies on fixed-time ovulation induction in the pig". Soc Reprod Fertil Suppl. 66: 187–95. PMID 19848281.
- ^ A. Labhart (6 December 2012). Clinical Endocrinology: Theory and Practice. Springer Science & Business Media. pp. 523–. ISBN 978-3-642-96158-8.
- ^ a b c JUCKER (21 December 2013). Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 102–. ISBN 978-3-0348-7065-8.
- v
- t
- e
Progestogens and antiprogestogens
(and progestins)
| SPRMsTooltip Selective progesterone receptor modulators | |
|---|---|
| PRTooltip Progesterone receptor antagonists |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
- See also
- Progesterone receptor modulators
- Androgens and antiandrogens
- Estrogens and antiestrogens
- List of progestogens
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
